Disposition and Mass Balance of Etrasimod in Healthy Subjects and In Vitro Determination of the Enzymes Responsible for Its Oxidative Metabolism

Caroline A. Lee(Pfizer (United States)), John S. Grundy(Pfizer (United States)), Kye Gilder(VistaGen Therapeutics (United States)), Ping Yi(State Key Laboratory of Diagnosis and Treatment of Infectious Diseases), Mohammad Bashir(LabCorp (United States)), A. C. Blackburn(Pfizer (United States)), Yong Tang(Xihua University), D. Alexander Oh(Pfizer (United States)), Stephen English(Jacksonville College), Steve Bloom(Imperial College London), Marie Croft
Clinical Pharmacology in Drug Development
May 3, 2023
10.1002/cpdd.1255
Cited by 14

Related Papers

Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms
|Gut|2020|1.4k
Factors Associated With Prolonged Viral RNA Shedding in Patients with Coronavirus Disease 2019 (COVID-19)
|Clinical Infectious Diseases|2020|556
Appetite control
|Journal of Endocrinology|2005|431
Gastrointestinal hormones regulating appetite
|Philosophical Transactions of the Royal Society B Biological Sciences|2006|343
The obesity pipeline: current strategies in the development of anti-obesity drugs
|Nature Reviews Drug Discovery|2006|213